食管鳞癌新辅助化疗与化放疗后病理完全缓解者的生存差异
该研究整合7项III期随机对照试验的1044例可切除食管鳞癌患者个体数据,比较新辅助化疗(NAC)与新辅助化放疗(NACRT)的预后差异。NAC组与NACRT组的pCR率分别为6.9%与34.2%;在达到pCR的192例患者中,NAC组5年总生存率为97.5%,NACRT组为70.4%,多因素分析显示NAC组生存优势显著。
要点
- NAC组pCR率6.9%,NACRT组34.2%,但pCR后NAC组5年OS达97.5%。
- 达到pCR者中NAC组5年无复发生存率80.8%,NACRT组63.7%。
- pCR后NAC组生存优势显著,或为等待观察策略优选人群。
核心结论
- 在达到pCR的食管鳞癌患者中,NAC组的5年总生存率和无复发生存率均高于NACRT组,多因素分析显示NAC组生存优势显著。
研究设计与样本
- 整合分析7项III期随机对照试验的个体患者数据,共纳入1044例可切除食管鳞癌患者,其中605例(58.0%)接受NAC,439例(42.0%)接受NACRT。
主要发现
- NAC组与NACRT组的R0切除率分别为89.6%与84.7%,pCR率分别为6.9%与34.2%。
- 在达到pCR的192例患者中,NAC组5年总生存率为97.5%,NACRT组为70.4%。
- 在达到pCR的患者中,NAC组5年无复发生存率为80.8%,NACRT组为63.7%。
临床怎么用
- 对于接受NAC后达到pCR的食管鳞癌患者,其预后极佳,可考虑作为未来手术回避和等待观察策略评估的优选人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although several oesophageal squamous cell carcinoma (OSCC) studies have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pCR rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate endpoint, it remains uncertain whether survival differs between these modalities among patients with OSCC who achieve pCR. METHODS: An integrated analysis of individual patient data (IPD) from phase III trials evaluating perioperative therapies for resectable OSCC was conducted, emphasizing prognostic differences between NAC and NACRT, particularly among patients who achieved pCR. RESULTS: IPD from seven phase III RCTs across six countries included data for 1044 patients with OSCC (83.5% male; mean age of 62.3 years). Of these patients, 605 (58.0%) received NAC and 439 (42.0%) received NACRT, with R0 resection rates of 89.6% versus 84.7% and pCR rates of 6.9% versus 34.2% respectively. Among patients who achieved pCR (192 patients), 5-year OS was 97.5% in the NAC group and 70.4% in the NACRT group, while 5-year recurrence-free survival was 80.8% and 63.7% respectively. Multivariable analysis demonstrated a significant survival advantage for NAC among patients who achieved pCR. CONCLUSION: Among patients who achieved pCR, postoperative outcomes varied considerably by neoadjuvant treatment modality. The markedly favourable prognosis associated with pCR after NAC suggests that these patients may represent an optimal candidate cohort for future evaluation of surgery-avoidance and watch-and-wait strategies.
引用
- Okui J, Matsuda S, Nagashima K, et al. Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma. Br J Surg. 2026. PMID: 41699916. doi:10.1093/bjs/znag012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。